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Abstract 
This paper addresses a family of issues surrounding 
the biological phenomenon of resistance and its rep-
resentation in realist ontologies. Resistance terms 
from various existing ontologies are examined and 
found to be either overly narrow, inconsistent, or 
otherwise problematic. We propose a more coherent 
ontological representation using the antibiotic resis-
tance in Methicillin-Resistant Staphylococcus aureus 
(MRSa) as a case study.   
Introduction: IDO, SaIDO, and MRSa 
The phenomenon of resistance is an important feature 
of biological reality, encompassing phenomena such 
as the resistance of an individual to specific diseases, 
the resistance of disorders to specific treatments, and 
the resistance of certain pathogens to certain drugs. 
As such, resistance is a phenomenon that needs to be 
captured in biomedical ontologies. 
The Infectious Disease Ontology (IDO) consortium is 
developing a set of interoperable ontologies that to-
gether are intended to provide coverage of the infec-
tious disease domain. At the core of the set is IDO 
itself, which provides a representation of all of these 
types of entities, drawn from both the biomedical and 
the clinical domains that are relevant to infectious 
diseases in general.  Domain-specific extensions (e.g., 
pathogen-specific extensions) of this core IDO com-
plete the set by providing ontology coverage of enti-
ties relevant to specific sub-domains of the infectious 
disease field. IDO is itself an extension of the Basic 
Formal Ontology (BFO). 
The Staphylococcus aureus Infectious Disease On-
tology (SaIDO) is an extension of IDO concerning 
Staph aureus (Sa) infection. Sa can be partitioned 
into two subtypes: Methicillin-Susceptible Sa (MSSa) 
and Methicillin-Resistant Sa (MRSa).  The latter sub-
type is a defined class that is distinguished by its re-
sistance to methicillin (and other β-lactam antibiot-
ics). Due to its rapid evolution in the face of antibi-
otic selective pressures, MRSa has become the para-
digm of resistance (a so-called “superbug”), and has 
drawn significant attention from NIAID/NIH, CDC, 
and biomedical researchers throughout the developed 
world. 
Subtypes of Sa can also be specified by assigning 
bacterial strains to clonal complexes based on geno-
typic differences. Variants can differ in their degree 
of resistance and in the types of drug to which they 
are resistant, forming a continuum, in terms of which 
Sa can be (and is) categorized. This provides one 
powerful reason to produce an ontologically correct 
representation of resistance. 
In this communication, we consider the issues arising 
from the representation of resistance in realist ontolo-
gies and specifically, in IDO. We will focus our atten-
tion on the antibiotic resistance of MRSa to methicil-
lin as a case-study.  
Ontological Issues Stemming from Resistance 
An important principle for realist ontology develop-
ment is to avoid as far as possible the use of negative 
differentia (e.g., ‘nonphysical’, ‘not part of the heart’) 
in formulating definitions. This “positivity design 
principle” enforces the use of terms which capture 
information about the entities represented in the on-
tology rather than information about the state of our 
knowledge at some given time.1  
At some level, however, resistance seems to require a 
negative aspect for its description. After all, a contin-
uant is resistant precisely when something does not 
happen. John’s resistance to marriage entails a host of 
processes that do not happen (for example, John does 
not buy an engagement ring, does not get a marriage 
license, and so forth). In the case of MRSa, resistance 
to methicillin entails that a process of cell wall forma-




































negativity of resistance is only a semantic feature of 
the description at some level. The biological phe-
nomenon of resistance is manifested at various levels 
of biological reality: genes, cells and their parts, or-
ganisms, and populations. Negative descriptions at a 
macro-scale here mask the positive and active aspects 
of resistance at the micro-scale. A comprehensive 
ontological treatment must, accordingly consider re-
sistance at different levels of granularity.   
In BFO-based ontologies, the lacks relation can be 
used to capture negative findings at one scale of bio-
logical description while avoiding the problems of 
using negative predicates or characteristics.2 In de-
scribing resistance, we will have a need to say that an 
independent continuant does not exhibit a dependent 
continuant.  As we will see below, this amounts to an 
independent continuant lacking a certain disposition.  
Resistance is referred to by several disciplines: epi-
demiologists describe the spread of resistance in a 
population, the medical community speaks of patient 
resistance to disease and pathogen resistance to drugs, 
and geneticists make reference to the genes that con-
fer resistance when certain alleles are present. The 
IDO suite of ontologies must capture all of these dis-
cipline-specific aspects of resistance and the relations 
between them. 
Resistance in Existing Ontologies 
We surveyed the treatment of resistance in existing 
ontologies.  
Gene Ontology (GO). A general treatment of resis-
tance is outside the scope of the GO, as resistance is 
not a biological process, molecular function, or cellu-
lar component. Within the sub-ontology of biological 
processes, however, GO contains the term ‘response 
to drug’, with synonyms ‘drug resistance’ and ‘drug 
susceptibility/resistance’. 
 
[GO:0042493] Response to Drug:  A change in state 
or activity of a cell or an organism (in terms of 
movement, secretion, enzyme production, gene ex-
pression, etc.) as a result of a drug stimulus. 
 
This treatment is inadequate because the narrower 
term “drug resistance” is made a synonym of the 
broader term “response to drug”. Resistance arises 
spontaneously as the result of genetic diversification. 
The presence of the drug provides a fitness advantage 
to those cells or viral particles that have the resistance 
conferring gene or mutation, thus they outcompete the 
susceptible individuals. The resistance is not a direct 
response to the drug stimulus, although the manifesta-
tion of resistance may be a consequence of exposure 
to the drug. A response to a drug is a process, 
whereas resistance is a continuant.  This error (al-
though GO usually is very good at preventing this 
confusion), arises from an inadequate analysis of re-
sistance. Finally, the GO definition of drug resistance 
seems to hinge on a ‘change in state’, but cells which 
do not change state are manifesting a ‘response to a 
drug’ just as much as those which do.  
 
NCI Thesaurus. The NCI Thesaurus has the following 
entry for ‘resistance’: 
 
[C19391] Resistance: Natural or acquired mecha-
nisms, functions, activities, or processes exhibited by 
an organism to maintain immunity to, or to resist the 
effects of, an antagonistic agent, e.g., pathogenic mi-
croorganism, toxin, drug. 
 
The primary problems with this treatment of resis-
tance are that: i) the definition is circular, since it uses 
‘resist’ in defining ‘resistance’, and ii) the term ‘resis-
tance’ is a child of “resistance process”, making resis-
tance a process, as in the GO, and excluding many 
types of resistance, because the definition of ‘resis-
tance process’ is biased towards multicellular organ-
ism resistance mediated by host defense mechanisms.  
 
SNOMED-CT. SNOMED-CT contains the entry 
‘drug resistance (disorder)’ with two defining rela-
tionships: 
 
Drug Resistance Is a Drug-Related Disorder  
Drug Resistance has Causative Agent (Attribute) 
Drug or Medicament.  
 
With a parent term like ‘drug-related disorder’, it is 
clear that this definition is given from the perspective 
of the patient.  From the perspective of a pathogen 
(qua organism) or tumor, for example, drug resis-
tance is not a disorder, but rather a benefit. Also, the 
definition specifies that drug resistance is caused by a 
drug, but resistance is caused typically by the pres-
ence of a gene or mutation. It is only the manifesta-
tion of resistance that results from the presence of the 
drug. Finally, as with other terms in SNOMED, only 
necessary but not sufficient conditions for drug resis-
tance are provided.  Good definitions should spell out 
both. 
 
Infectious Disease Ontology (IDO). IDO includes the 
term ‘protective resistance’, the definition of which 
attempts to address some of these problems: 
 
Protective resistance is a disposition that inheres in 




































has a part (e.g., a gene product), the disposition of 
which is to ensure a physiologic response of a certain 
degree to a potentially damaging entity P, or to pre-
vent the completion of some process caused by P, 
thereby protecting the organism from or mitigating 
the damaging effects of P. 
 
In the next section, we describe the ontological case 
study that helped lead us to this definition. 
Towards a More Robust Ontological Treatment  
To better understand the representational demands 
posed by resistance (and to expose the problems 
raised by this and similar phenomena from an onto-
logical point of view), it will be useful to go through a 
detailed example. We choose drug resistance for a 
single combination of pathogen, antibiotic, and resis-
tance-mechanism types. In this section we will sketch 
the outlines of a formal representation of the resis-
tance of MRSa to methicillin as conferred by PBP2a, 
a penicillin binding protein (PBP) and a product of 
the gene mecA. Both methicillin and penicillin are β-
lactam antibiotics and, for the purposes of our formal-
ization, a PBP can be considered to be a methicillin 
binding protein. Chambers3 gives a concise descrip-
tion of this form of resistance: “[M]ethicillin resis-
tance in staphylococci is due to expression of PBP2a, 
a novel, low-affinity PBP for which there is no homo-
logue in methicillin-susceptible strains”. We formal-
ize this information as a set of triples expressing the 
relevant ontological relationships. We also include a 
series of inference rules that would lead a logic-
driven reasoner to deduce from the triples that MRSa 
is resistant to methicillin. Alongside the statistical 
techniques employed in biology, it will one day be 
desirable for automated reasoners to compute antibi-
otic resistance from logical formalizations. Using 
ontologies as predictive tools will guide treatment 
decisions and support automated drug discovery. 
 
The terms used in our representation will be derived 
from IDO, GO, and the Protein Ontology. The 
relations used are drawn from the OBO Relation 
Ontology (RO) and its extensions (see 
http://www.obofoundry.org/ro/). Naïvely, we could 
introduce a new relation resistant_to and represent 
the entire situation as MRSa resistant_to methicillin. 
However, this would hide the complexity of the 
mechanisms of resistance working at a smaller scale 
and elminate many important inferences about 
resistance. Also, it is important to avoid a 
proliferation of relations in the OBO Foundry, since 
restriction to a small set of relations promotes reuse 
and interoperability of the constituent ontologies.   
 
A more faithful representation requires at least the 
following components (where is_a and has_part are 
used for relations between both continuant and oc-
curent universals): 
 
[1] bacterium is_a organism 
[2] MRSa is_a bacterium 
[3] synthesis_of_peptidoglycan is_a process and 
has_participant Penicillin_Binding_Protein (PBP) 
[4] PBP has_function_realized_as_process 
synthesis_of_peptidoglycan 
[5] Bacterial_cell_wall is_location_of PBP  
[6] Canonically, synthesis_of_peptidoglycan 
results_in_development_of  bacterial_cell_wall 
[7] formation_of_bacterial_cell_wall is_a process 
[8] PBP2a is_a PBP 
[9] methicillin_PBP_binding_process is_a binding process 
that has_participants methicillin and PBP  
[10] affinity_to_methicillin disposition_of some PBP to 
undergo a methicillin_PBP_binding_process that is 
realized in the presence of a methicillin. 
[11] methicillin_PBP_binding_process 
negatively_regulates synthesis_of_peptidoglycan. 
[12] PBP2a lacks affinity_to_methicillin 
[13] mecA is_a gene 
[14] MRSa has_part mecA 
[15] mecA generically_specifies PBP2a_production 
[16] PBP2a_production results_in_formation_of PBP2a 
 
These triples will be used along with several rules of 
inference and derived facts (labeled IRn and Dn re-
spectively in what follows).  For readability, all vari-
ables are italicized and initial universal quantifier 
symbols are suppressed. First, we specify that is_a 
and has_part (for both continuants and occurrents) 
are transitive, allowing us to derive some basic taxo-
nomic facts about the domain: 
 
(IR1) x is_a y & y is_a z → x is_a z 
(IR2) x has_part y & y has_part z → x has_part z 
(D1) MRSa is_a organism  
 
The parts of an organism are the products of the or-
ganism’s expressed genes, and these products are 
located in the appropriate places: 
 
(IR3) (o is_a organism & g is_a gene & o has_part g &  
g generically_specifies proc &  
proc results_in_formation_of prod &  
o has_part locp &  locp is_location_of prod) →  
o has_part prod located_in locp 
(D2) MRSa has_part PBP2a located_in bacterial_cell_wall  
 
The inference rule (IR3) makes a few simplifying 
assumptions. Since not all genes are expressed, we 
are only modeling the situation in which g is an ex-
pressed gene. We also assume that the process proc 
leading to prod is active, and that the single gene g 





































If a continuant lacks a disposition to undergo a proc-
ess in some situation, and that process negatively 
regulates a second process which has the continuant 
as a participant, then the continuant participates in the 
second process in that situation: 
 
(IR4) p lacks disposition to undergo proc1 realized in situation s 
  & proc1 negatively_regulates proc2  
& proc2 has_participant p →  
In situation s, p participates_in proc2 
(D3) In the presence of methicillin, PBP2a participates_in 
synthesis_of_peptidoglycan. 
 
This lack of a disposition (i.e., the affinity to methi-
cillin) has a categorical basis in the fact that methicil-
lin binds to PBPs and prevents them from carrying 
out their function. However, PBP2a lacks this affin-
ity, so the presence of methicillin does not prevent the 
essential sub-processes of cell-wall construction in 
MRSa.  
 
If an organism has a continuant as a part and that part 
participates in a process in some situation, then the 
process unfolds in the organism in that situation. Fi-
nally, if a process unfolds in an organism in some 
situation and the process results in the development 
of a continuant which (canonically) is a part of the 
organism, then the organism has the continuant as a 
part in that situation. 
 
(IR5) In situation s, p1 participates_in proc & p1 located_in p2 
& o has_part p2 → proc unfolds_in o in situation s. 
(D4) synthesis_of_peptidoglycan unfolds_in MRSa in the 
presence of methicillin. 
(IR6) In situation s, proc unfolds_in o &  
Canonically, proc results_in_development_of p →  
p part_of o in situation s 
(D5) Bacterial_cell_wall part_of MRSa in the presence of 
methicillin. 
 
The canonical cell wall is a rigid configuration of 
peptidoglycan. From the perspective of MRSa, the 
canonical cell wall is a healthy one. The assertion 
(D5) captures the active, and thus positive, micro-
physical side of the resistance coin. 
 
However the chain of reasoning here presents a puz-
zle. What does the lack of a disposition in (IR4) 
amount to?  Consider the following pair:  
 
(A) Continuant C lacks disposition D to undergo process P in 
situation S 
(B) Continuant C undergoes P in a situation of type S.   
 
Both (A) and (B) can be true at the same time.  In fact 
the conjunction of (A) and (B) implies that (B) hap-
pens for a non-dispositional reason (i.e., (B) is not, in 
the corresponding case, a manifestation of the dispo-
sition D). Even if John lacks the disposition to feel 
hungry when in the presence of sushi, he may still feel 
hungry in such a situation because he has been fasting 
for three days.  We need a way to say that PBP2a 
necessarily lacks affinity to methicillin in order to 
permit the relevant cell-wall formation. 
Mereological Issues 
If we take resistance to be a specifically dependant 
continuant that inheres in an independent continuant, 
then we must still answer some mereological ques-
tions: Is the resistance of PBP2a (i.e., of a part) iden-
tical to the resistance of the cell (i.e., of the including 
whole)? Furthermore, is cell resistance identical to 
the resistance of a portion of tissue in which the cell 
resides or the containing host organism or, for that 
matter, of the containing population?  The ontology 
of resistance must address which scales of biological 
reality resistant continuants occupy, and the identity 
of resistance across scales. 
 
Another issue that should be addressed at different 
scales of biological reality is the way in which facts at 
each scale are used to explain the phenomenon of 
resistance.  At the genetic scale, MRSa having mecA 
and MSSa lacking mecA are explanatory.  At the cel-
lular level (D5) is explanatory. 
Conclusion 
We have seen that resistance is an important multi-
scale and multi-domain phenomenon, often with 
a one-to-many relationship between a resistant organ-
ism and the underlying mechanisms of resistance. 
Several desiderata for an ontological representation 
were found lacking in existing ontologies. Our pre-
liminary formalization of resistance honors both a 
positivity design principle and a principle of non-
proliferation of relations, both of which are sound 
principles for the design of effective ontologies.  
Some puzzles remain (e.g., an account for the lack of 
a disposition), but further study of resistance will 
have great benefits for biomedical ontologies. 
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